These findings may have implications in the choice of anti-hypertensive medication because, in hypertension patients who harbor Rgs2 mutations that decrease protein expression and/or function, therapies that concurrently target vasoconstrictor and tubular GPCR signaling may be more effective drug of choice than those drugs that only affect one aspect of renal function. The gene discussed is RGS2; the disease is hypertensive disorder.